Live Status Check

NCT02934568 Recruiting Status

Real-time enrollment status for this i cannot determine the primary medical condition from the provided information. the study title only mentions it's a "rollover study for continued access" for ribociclib (lee011), and the conditions listed are just the drug names. the brief summary appears to be incomplete (showing only "localhost:3000/trial/"). without additional clinical context about what condition ribociclib treats, i cannot extract the patient-facing medical condition. clinical trial

Current Status

Active, Not Recruiting

Auto-verified from ClinicalTrials.gov

Checked: March 2, 2026 at 8:49 AM UTC

NCT02934568 Status Summary

NCT NumberNCT02934568
Recruiting StatusActive, Not Recruiting
ConditionI cannot determine the primary medical condition from the provided information. The study title only mentions it's a "rollover study for continued access" for Ribociclib (LEE011), and the conditions listed are just the drug names. The brief summary appears to be incomplete (showing only "localhost:3000/trial/"). Without additional clinical context about what condition Ribociclib treats, I cannot extract the patient-facing medical condition.
PhaseClinical Trial
Target Enrollment50 participants
Active Locations5 sites in the US
SponsorNovartis Pharmaceuticals
Last Updated on CT.govFebruary 12, 2026 (2 weeks ago)

About NCT02934568 Enrollment Status

As of March 2, 2026: Clinical trial NCT02934568 is currently active_not_recruiting participants. This clinical trial study for i cannot determine the primary medical condition from the provided information. the study title only mentions it's a "rollover study for continued access" for ribociclib (lee011), and the conditions listed are just the drug names. the brief summary appears to be incomplete (showing only "localhost:3000/trial/"). without additional clinical context about what condition ribociclib treats, i cannot extract the patient-facing medical condition. is not currently accepting new participants at 5 locations across the United States. The study is sponsored by Novartis Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.

Frequently Asked Questions About NCT02934568

Is NCT02934568 still recruiting?

No, NCT02934568 is currently active_not_recruiting. The study may resume recruiting in the future.

Where is NCT02934568 recruiting?

This trial is recruiting at 5 locations in the United States. View all available locations on the full study page.

How do I enroll in NCT02934568?

Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.

When was NCT02934568 status last updated?

The official ClinicalTrials.gov record for NCT02934568 was last updated 2 weeks ago (February 12, 2026). HelloStudys verifies this status automatically.

Browse More I cannot determine the primary medical condition from the provided information. The study title only mentions it's a "rollover study for continued access" for Ribociclib (LEE011), and the conditions listed are just the drug names. The brief summary appears to be incomplete (showing only "localhost:3000/trial/"). Without additional clinical context about what condition Ribociclib treats, I cannot extract the patient-facing medical condition. Trials

Want to Learn More?

View full study details and sign up for status updates